After a conference lacking the wow factor, biotech winners and losers emerge.
ApexOnco Front Page
Recent articles
16 September 2024
Despite seeing dose-limiting toxicities, the group is going higher with its KRAS G12D project.
29 July 2024
Meanwhile, the RayzeBio-originated RYZ101 is back in Action.
29 July 2024
Now in Bristol’s hands, BMS-986442 is set to deliver its first clinical data.
26 July 2024
But Imfinzi's precise setting is uncertain, and big problems loom for companies pursuing similar trials.
25 July 2024
Roche curbs its TIGIT push, while a co-stimulation crunch could be bad news for Regeneron.
24 July 2024
Soon after filing to float in Hong Kong, Baili takes HER2 and DLL3-targeting ADCs into the clinic.
24 July 2024
An adcom on Imfinzi’s Aegean trial will show whether neoadjuvant and adjuvant benefits must be split out.
Recent Quick take
- 8 May 2024
- 8 May 2024
- 7 May 2024
- 7 May 2024
- 2 May 2024
- 29 April 2024
- 26 April 2024